Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETERMINE Arm 07: Dabrafenib and Trametinib in BRAF V600 Mutated Cancers
NCT07440290Phase 3Recruiting
- Sponsor
- Cancer Research UK
- Start
- Apr 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dabrafenib + trametinib and trametinib in cancer, sponsored by Cancer Research UK. Primary endpoints: Objective response up to 24 weeks and Durable Clinical Benefit up to 24 weeks. Started Apr 2026; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07440290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07440290.